Accretion Pharmaceuticals Limited (NSE:ACCPL)
India · Delayed Price · Currency is INR 202.30
-5.70 (-2.74%)
At close: Aug 21, 2026
Accretion Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 896.27 | 573.76 | 133.53 | 293.84 | 222.92 |
Other Revenue | - | - | - | 1.47 | 2.92 |
| 896.27 | 573.76 | 133.53 | 295.32 | 225.84 | |
Revenue Growth | 56.21% | 329.70% | -54.79% | 30.76% | - |
Cost of Revenue | 656.46 | 400.22 | 94.36 | 240.11 | 179.93 |
Gross Profit | 239.81 | 173.55 | 39.17 | 55.21 | 45.91 |
Selling, General & Admin | 48.99 | 37.76 | 9.09 | 25.21 | 19.75 |
Other Operating Expenses | 40.23 | 16.76 | 4.27 | 8.61 | 6.84 |
Operating Expenses | 101.33 | 62.26 | 15.59 | 43.06 | 34.7 |
Operating Income | 138.48 | 111.29 | 23.58 | 12.15 | 11.21 |
Interest Expense | -7.4 | -13.87 | -2.57 | -10.25 | -9.98 |
Interest & Investment Income | 0.04 | - | - | - | - |
Currency Exchange Gain (Loss) | 0.88 | 0.47 | 0.11 | - | - |
Other Non Operating Income (Expenses) | -1.18 | -0.25 | -1.17 | -0.51 | -0.19 |
Pretax Income | 130.83 | 97.64 | 19.95 | 1.39 | 1.04 |
Income Tax Expense | 34.16 | 29.7 | 5.02 | 0.35 | 0.25 |
Net Income | 96.68 | 67.94 | 14.93 | 1.04 | 0.79 |
Net Income to Common | 96.68 | 67.94 | 14.93 | 1.04 | 0.79 |
Net Income Growth | 42.30% | 355.08% | 1336.77% | 31.52% | - |
Shares Outstanding (Basic) | 11 | 8 | 8 | - | - |
Shares Outstanding (Diluted) | 11 | 8 | 8 | - | - |
Shares Change | 33.55% | 5.47% | - | - | - |
EPS (Basic) | 9.03 | 8.48 | 1.96 | - | - |
EPS (Diluted) | 9.03 | 8.48 | 1.96 | - | - |
EPS Growth | 6.54% | 332.43% | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -230.68 | -22.3 | -169.87 | -8.57 | 18.93 |
Free Cash Flow Per Share | -21.55 | -2.78 | -22.35 | - | - |
Gross Margin | 26.76% | 30.25% | 29.33% | 18.70% | 20.33% |
Operating Margin | 15.45% | 19.40% | 17.66% | 4.12% | 4.96% |
Profit Margin | 10.79% | 11.84% | 11.18% | 0.35% | 0.35% |
Free Cash Flow Margin | -25.74% | -3.89% | -127.22% | -2.90% | 8.38% |
EBITDA | 150.59 | 119.04 | 25.81 | 21.39 | 19.31 |
EBITDA Margin | 16.80% | 20.75% | 19.33% | 7.24% | 8.55% |
D&A For EBITDA | 12.11 | 7.75 | 2.24 | 9.23 | 8.1 |
EBIT | 138.48 | 111.29 | 23.58 | 12.15 | 11.21 |
EBIT Margin | 15.45% | 19.40% | 17.66% | 4.12% | 4.96% |
Effective Tax Rate | 26.11% | 30.42% | 25.17% | 25.14% | 24.04% |
Revenue as Reported | 898.18 | 574.71 | 134.07 | 295.32 | 225.84 |
Advertising Expenses | 0.7 | 0.17 | - | 0.16 | - |